Adriamycin — 2 mg/1 mL, Lyophilized powder for solution for injection, 1 × 25 mL vial in 1 box

Adriamycin — 2 mg/1 mL, Lyophilized powder for solution for injection, 1 × 25 mL vial in 1 box

Adriamycin (Doxorubicin Hydrochloride) is a lyophilized powder for solution for injection for intravenous use. Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1) . Supplied as 1 × 25 mL vial in 1 box; NDC 0143-9277-01; manufacturer Hikma Pharmaceuticals USA Inc. Rx only. Store all vials at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light.

• Active ingredient or product type: DOXORUBICIN HYDROCHLORIDE
• Strength/concentration: 2 mg/1 mL
• Dosage form and route: Lyophilized powder for solution for injection, Intravenous
• Exact package presentation: 1 × 25 mL vial in 1 box
• NDC/item number: 0143-9277-01
• Manufacturer/labeler: Hikma Pharmaceuticals USA Inc.
• Storage/handling: Store all vials at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light. The reconstituted solution is stable for 7 days at room temperature and under normal room light (100 foot-candles) and 15 days under refrigeration (2° to 8°C).
• Status: Rx only

Important safety information: Radiation-induced toxicity can be increased by the administration of doxorubicin.

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.